One of the founders of the ROS1ders, Janet Freeman-Daily, shares her story and why she advocates for molecular testing, clinical trials, and the positive changes she’s seen.
“Given that lung cancer patients often don’t have much tumor tissue, we should make the best use of it, and running an NGS test is the best chance that we have of finding a gene that might allow them to take an FDA-approved drug or get into a clinical trial,” Janet says. “A lot of people aren’t even being tested for ROS1, yet it has a targeted therapy that works in up to 80 percent of patients. I just need to get the word out about genomic testing because many times doctors just can’t keep up when the science is evolving so fast.”
Read the full interview here.